Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2018 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. The question asks if a substantial part of the forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's analyze the transcript. The call is about Fresenius Medical Care, a dialysis company. Management discusses various topics: Q2 results, guidance, Calcimimetics, Care Coordination, divestment of Sound, ESRD Prospective Payment System, ESCOs, Patients Act, MSP extension, etc. Key points: Management talks about its own business, its own growth, its own products, its own initiatives. They mention "Care Coordination" and "Calcimimetics" which are internal programs. They discuss the impact of currency, tax reform, etc. They talk about the ESRD rate proposal, which is a regulatory matter, not a counterparty's own trajectory. They discuss ESCOs (ESRD Seamless Care Organizations) which are a program they participate in, but they talk about waiting for CMS to allow expansion. That is more about regulatory approval than a counterparty's own scaling. They mention the Patients Act and MSP extension as legislative matters. The question specifically asks about narrating what counterparties are themselves doing and scaling. For example, if they talked about a major customer expanding their clinics, or a partner rolling out a new product, etc. Here, the counterparties could be payers, providers, or programs. But management's forward account seems to be about their own actions, their own product launches, their own cost programs, their own investments. They do mention "Vifor - Fresenius Medical Care joint venture" and "Veltassa developments" but that is a joint venture, not a counterparty they supply. They mention "Cura acquisition" in Asia Pacific, but that's an acquisition. They also discuss "Calcimimetics" which is a drug class, and they are transitioning from Part D to Part B, but that's about their own reimbursement and product mix.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.